Page last updated: 2024-08-23

atomoxetine hydrochloride and Cognitive Decline

atomoxetine hydrochloride has been researched along with Cognitive Decline in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Abrol, A; Calhoun, VD; Dammer, EB; Duong, DM; Edland, SD; Fagan, AM; Galasko, D; Gámez Tansey, M; Goldstein, DS; Goldstein, FC; Hajjar, I; Hales, CM; Hanfelt, J; Higginbotham, L; Hu, WT; Lah, JJ; Levey, AI; Qiu, D; Seyfried, NT; Weinshenker, D; Wingo, TS; Zhao, L	1
Bernadzikowski, T; Boris, JR	1
Brown, JN; Ottman, AA; Warner, CB	1

Reviews

1 review(s) available for atomoxetine hydrochloride and Cognitive Decline

Article	Year
The Role of Atomoxetine for Parkinson Disease-Related Executive Dysfunction: A Systematic Review. Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:6 Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Cognitive Dysfunction; Executive Function; Humans; Parkinson Disease	2018

Trials

1 trial(s) available for atomoxetine hydrochloride and Cognitive Decline

Article	Year
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain : a journal of neurology, 2022, 06-30, Volume: 145, Issue:6 Topics: Adolescent; Adult; Alzheimer Disease; Amyloid beta-Peptides; Antigens, Neoplasm; Atomoxetine Hydrochloride; Biomarkers; Cell Adhesion Molecules; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Method; Drug Repositioning; Humans; Inflammation; Middle Aged; Neuroprotection; Norepinephrine; tau Proteins	2022

Article

Year

A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.

Brain : a journal of neurology, 2022, 06-30, Volume: 145, Issue:6

Topics: Adolescent; Adult; Alzheimer Disease; Amyloid beta-Peptides; Antigens, Neoplasm; Atomoxetine Hydrochloride; Biomarkers; Cell Adhesion Molecules; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Method; Drug Repositioning; Humans; Inflammation; Middle Aged; Neuroprotection; Norepinephrine; tau Proteins

2022

Other Studies

1 other study(ies) available for atomoxetine hydrochloride and Cognitive Decline

Article	Year
Therapy for fatigue and cognitive dysfunction in postural orthostatic tachycardia syndrome. Cardiology in the young, 2018, Volume: 28, Issue:12 Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Central Nervous System Stimulants; Child; Cognitive Dysfunction; Databases, Factual; Drug Therapy, Combination; Drug Utilization; Fatigue; Female; Hospitals, Pediatric; Humans; Male; Methylphenidate; Philadelphia; Postural Orthostatic Tachycardia Syndrome; Retrospective Studies; Treatment Outcome	2018

Article

Year

Therapy for fatigue and cognitive dysfunction in postural orthostatic tachycardia syndrome.

Cardiology in the young, 2018, Volume: 28, Issue:12

Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Central Nervous System Stimulants; Child; Cognitive Dysfunction; Databases, Factual; Drug Therapy, Combination; Drug Utilization; Fatigue; Female; Hospitals, Pediatric; Humans; Male; Methylphenidate; Philadelphia; Postural Orthostatic Tachycardia Syndrome; Retrospective Studies; Treatment Outcome

2018